Zhongke Yian Medical Technology Launches High-nitrogen Nickel-free Stainless Steel Coronary Stent System

Zhongke Yian Medical Technology (Beijing) Co., Ltd. announced today the official market approval and launch of its innovative Sirolimus Drug-Eluting Coronary Stent System. Approved on July 18, 2025, by the National Medical Products Administration (NMPA) through a fast-track innovation channel, this product marks a significant advancement in cardiovascular treatment.

The new stent system is the first in China to combine a high-nitrogen nickel-free stainless steel stent base with precision drug coating technology, providing a safer and more effective treatment option for patients with ischemic heart disease.

The Following Unique Features were pointed out by the manufacturer:

  • High-Nitrogen Nickel-Free Stainless Steel: This advanced material eliminates the risk of nickel allergies, a concern with traditional nickel-titanium alloys. It also enhances the stent’s radial support strength and corrosion resistance, ensuring long-term structural integrity.
  • Precision Drug Release: The system utilizes a sirolimus drug combined with a PLGA coating, delivering a precise dosage of 100 μg/cm². Through sustained-release technology, the stent effectively reduces restenosis rates while promoting vascular healing.
  • Optimized Delivery System: Designed for surgical efficiency, the rapid-exchange balloon catheter is suitable for lesions in vessels ranging from 2.5 to 4.0 mm in diameter, making it compatible with a wide range of patient anatomies.